T: 0208 731 5288

Caring for others has been a great privilege

April 01, 2019

After reading a www.iswwatches.combarrage of negativity about the poor care of our elderly, I found myself reflecting on the real essence of care. During my 30-year career as a nurse and manager privately and in the NHS, I have encountered human beings at their most vulnerable. I have had the privilege to hold the hands of many people as they have taken their last breath or spoken a final word. I have offered comfort to a mother who has lost her child and watched the joy on new parents� faces. I have shared tears of happiness and heartbreak, felt thanks in a hug and sometimes just in a look. The most precious gift that you can give to anyone is your time.https://womens-jewelry.kenkashoes.com/ Challenges around staffing and budgets face us daily,breitling replica watches yet if we keep the focus on those we are trusted to care for this should give us the sense of purpose for which we signed up and provide comfort for those who need it. I am proud and still now feel it a great privilege to be a nurse. To simply be kind always to those people we care for and to one another is a relatively simple goal. It comes from within us, and not from a spreadsheet. best casual watches

Back

Will Robots Provide Care In The Future!

November 10, 2019

The government has announced £34 million will be spent on designing robots capable of supporting people in the UK with care needs. The research will focus on making autonomous systems safe and trustworthy for public use, so in the future robots could perhaps help an elderly person up after a fall and raise the alarm, deliver food to an older person at mealtimes, and ensure they take medication at the correct time. (Previous research has cast doubt on whether robots are capable of the 'human touch' needed to carry out care tasks.)www.iswwatches.com

Back

Alzheimers - A new drug to slow the disease!

November 10, 2019

A US drug company www.iswwatches.com has created a drug that could slow Alzheimer's disease, and could soon be available to patients with early signs of the disease. Drug company Biogen said it is seeking regulatory approval for the drug called aducanumab next week after new analysis revealed it had helped reduce the clinical decline of early signs of Alzheimer’s. This will be the first treatment available to help slow Alzheimer’s disease and could soon be available to millions around the world. Biogen said some patients had experienced benefits in the areas of memory and language. ’People affected by Alzheimer’s have waited a long time for a life-changing new treatment’ It would be the first real treatment for Alzheimer’s disease, which affects around 500,000 people in the UK. Hilary Evans, chief executive at Alzheimer’s Research UK, said: “People affected by Alzheimer’s have waited a long time for a life-changing new treatment and this exciting announcement offers new hope that one could be in sight. “Taking another look at aducanumab is a positive step for all those who took part in the clinical trials and the worldwide dementia research community. "As more data emerges, we hope it will spark global discussions about the next steps for delivering much-needed treatments into people’s hands.” Aducanumab is an antibody designed to target amyloid, a protein that builds up in the brains of people with Alzheimer’s at an early stage in the disease process. Biogen originally halted clinical trials of aducanumab, called ENGAGE and EMERGE earlier this year when early indications suggested they would not benefit people in the early stages of Alzheimer’s disease, however, the new announcement suggests that the trial EMERGE met its primary goal of reducing cognitive decline in people who took aducanumab. Biogen said participants who were followed after the trials stopped, those who received greater exposure to high dose aducanumab showed a significant slowing in clinical decline. Biogen also believes that a subset of people involved in the ENGAGE trial also benefitted from high doses of the drug. Biogen is now planning a new study to re-offer the drug to eligible participants from their earlier trials of aducanumab. The drug will need to be approved by regulators before it could be offered more widely to the general population. 'It’s only through a sustained commitment to dementia research that will we make breakthroughs possible' Biogen has announced they plan to file for the market approval for aducanumab with American drug regulator, the FDA, in early 2020. Ms Evans said: “The FDA will now assess the new data and its strengths and limitations before deciding about whether aducanumab should be made widely available in the US. "At Alzheimer’s Research UK, we are already bringing together regulators and drug developers to help speed up the delivery of promising new treatments towards patients. This important work now has renewed urgency. “It’s only through a sustained commitment to dementia research that will we make breakthroughs possible that keep people connected to their families, their worlds and themselves for longer.”

Back

Would you like to work for top UK employers?

Submit Your CV

Register as a candidate and find out how Oakley Professional can help you in your search for a permanent or Contract job.

Get Start

Client Area

Login